» Articles » PMID: 30671946

Membrane Metallo-endopeptidase Mediates Cellular Senescence Induced by Oncogenic PIK3CA Accompanied with Pro-tumorigenic Secretome

Overview
Journal Int J Cancer
Specialty Oncology
Date 2019 Jan 24
PMID 30671946
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The hotspot mutation H1047R in the oncogenic PIK3CA gene is frequently detected in breast cancer and enhances the enzymatic activity of PI3K to activate AKT/mTOR signaling cascade. Aberrant elevated PI3K activation has been reported to promote the tumorigenesis of breast cancer, but the mechanisms underlying are still needed to be elucidated. Here, we found that continuously activating PIK3CA conferred human mammary epithelial MCF-10A cells to cellular senescence upon serum-starvation. Similarly, breast cancer T47D and HCC1954 cells harboring H1047R mutation were senescent when cells were deprived of serum. PI3K/AKT/mTOR axis but not p53 or RB might be required for the induction of senescence. Notably, membrane metallo-endopeptidase (MME) was identified as a downstream effector of PI3K to mediate the induction of senescence, which might be associated with its glycosylation. Senescent cells elicited a distinct secretome dependent on PI3K and MME. Specifically, IL-6 promoted the proliferation of normal cells and CCL2 induced the M2-like polarization of macrophages, which might create an immunosuppressive microenvironment during the initiation and/or development of breast cancer. This study shed new light on the tumorigenesis induced by hyper-activated PI3K and might provide new clues for the prevention and therapy of breast cancer.

Citing Articles

Comprehensive assessment of cellular senescence in intestinal immunity and biologic therapy response in ulcerative colitis.

Yao B, Zhang Y, Wu Q, Yao H, Peng L, Jiang Z Sci Rep. 2024; 14(1):28127.

PMID: 39548254 PMC: 11568168. DOI: 10.1038/s41598-024-79607-5.


Targeting senescence-associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes.

Xiong J, Dong L, Lv Q, Yin Y, Zhao J, Ke Y Clin Transl Med. 2024; 14(9):e1772.

PMID: 39270064 PMC: 11398298. DOI: 10.1002/ctm2.1772.


Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors.

Zhang J, Yin G, Ye C, Feng M, Ji C, Zhou W Chin J Cancer Res. 2024; 36(2):124-137.

PMID: 38751436 PMC: 11090794. DOI: 10.21147/j.issn.1000-9604.2024.02.03.


Exploring the molecular mechanism of hepatitis virus inducing hepatocellular carcinoma by microarray data and immune infiltrates analysis.

Zhang Y, Zeb A, Cheng L Front Immunol. 2022; 13:1032819.

PMID: 36439183 PMC: 9697180. DOI: 10.3389/fimmu.2022.1032819.


The Impact of Oxidative Stress and AKT Pathway on Cancer Cell Functions and Its Application to Natural Products.

Shiau J, Chuang Y, Tang J, Yang K, Chang F, Hou M Antioxidants (Basel). 2022; 11(9).

PMID: 36139919 PMC: 9495789. DOI: 10.3390/antiox11091845.